$96.43
+0.24%
N/A+$0.23
헬스케어
바이오테크놀로지
NASDAQ
활발히 거래 중
Celcuity, Inc.는 세포 분석 회사로 활동한다. 이 회사는 새로운 암 하위 유형을 발견하고, 표적 치료로 치료받는 암 환자의 임상적 결과를 개선하도록 설계된 ...
Celcuity, Inc.는 세포 분석 회사로 활동한다. 이 회사는 새로운 암 하위 유형을 발견하고, 표적 치료로 치료받는 암 환자의 임상적 결과를 개선하도록 설계된 ...
| 날짜 | 임원 | 직책 | 증권 | 구분 | 주식 수 | 가격 |
|---|---|---|---|---|---|---|
| Aug 14, 2026 | Laing Lance G. | director, officer: Chief Science Officer | Common Stock | A | 20,000 | — |
| Aug 14, 2026 | Laing Lance G. | director, officer: Chief Science Officer | Performance Stock Units | A | 10,000 | — |
| Aug 14, 2026 | Sullivan Brian F. | director, officer: Chief Executive Officer | Common Stock | A | 80,000 | — |
| Aug 14, 2026 | Sullivan Brian F. | director, officer: Chief Executive Officer | Performance Stock Units | A | 120,000 | — |
| Aug 14, 2026 | Hahne Vicky | officer: Chief Financial Officer | Common Stock | A | 16,000 | — |
매수/매도 주식 수와 종가 추세(공통 일간 가격 소스)
X축: 주식 수, 총 주식 수 내림차순
X축: 건수, A+D 건수 내림차순
| 날짜 | 임원 | 직책 | 증권 | 구분 | 주식 수 | 가격 | 금액 |
|---|---|---|---|---|---|---|---|
| Aug 14, 2026 | Laing Lance G. | director, officer: Chief Science Officer | Common Stock | A | 20,000 | — | — |
| Aug 14, 2026 | Laing Lance G. | director, officer: Chief Science Officer | Performance Stock Units | A | 10,000 | — | — |
| Aug 14, 2026 | Sullivan Brian F. | director, officer: Chief Executive Officer | Common Stock | A | 80,000 | — | — |
| Aug 14, 2026 | Sullivan Brian F. | director, officer: Chief Executive Officer | Performance Stock Units | A | 120,000 | — | — |
| Aug 14, 2026 | Hahne Vicky | officer: Chief Financial Officer | Common Stock | A | 16,000 | — | — |
| Aug 14, 2026 | Hahne Vicky | officer: Chief Financial Officer | Performance Stock Units | A | 10,000 | — | — |
| Jul 14, 2026 | BAKER BROS. ADVISORS LP | other: Former 10% owner | Common Stock | D | 2,838,632 | $102.50 | $290,959,780.00 |
| Jul 14, 2026 | BAKER BROS. ADVISORS LP | other: Former 10% owner | Common Stock | D | 261,368 | $102.50 | $26,790,220.00 |
| Jun 10, 2026 | Murphy Polly A. | director | Stock Option (right to buy) | A | 14,048 | $10.69 | $150,173.12 |
| Jun 10, 2026 | Murphy Polly A. | director | Stock Option (right to buy) | D | 14,048 | $10.69 | $150,173.12 |